1
|
Vasiljeva J, Makrecka-Kuka M, Domracheva I, Vilks K, Dimitrijevs P, Arsenyan P. Development of prospective non-toxic inhibitors of ABCB1 activity and expression in a series of selenophenoquinolinones. NEW J CHEM 2022. [DOI: 10.1039/d2nj00340f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Selenophenoquinolinone is a prospective scaffold for the development of ABCB1 inhibitors for the treatment of MDR cancers.
Collapse
Affiliation(s)
- Jelena Vasiljeva
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia
| | | | - Ilona Domracheva
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia
| | - Karlis Vilks
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia
| | - Pavels Dimitrijevs
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia
| | - Pavel Arsenyan
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia
| |
Collapse
|
2
|
Schaller D, Hagenow S, Stark H, Wolber G. Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands. PLoS One 2019; 14:e0218820. [PMID: 31237914 PMCID: PMC6592549 DOI: 10.1371/journal.pone.0218820] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Accepted: 06/10/2019] [Indexed: 12/25/2022] Open
Abstract
In this study, we report a ligand-guided homology modeling approach allowing the analysis of relevant binding site residue conformations and the identification of two novel histamine H3 receptor ligands with binding affinity in the nanomolar range. The newly developed method is based on exploiting an essential charge interaction characteristic for aminergic G-protein coupled receptors for ranking 3D receptor models appropriate for the discovery of novel compounds through virtual screening.
Collapse
Affiliation(s)
- David Schaller
- Molecular Design Lab, Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| | - Stefanie Hagenow
- Institute of Pharmaceutical and Medicinal Chemistry, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
| | - Gerhard Wolber
- Molecular Design Lab, Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| |
Collapse
|
3
|
Baakman AC, Zuiker R, van Gerven JMA, Gross N, Yang R, Fetell M, Gershon A, Gilgun-Sherki Y, Hellriegel E, Spiegelstein O. Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers. Br J Clin Pharmacol 2019; 85:970-985. [PMID: 30710391 DOI: 10.1111/bcp.13885] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 12/19/2018] [Accepted: 01/07/2019] [Indexed: 01/27/2023] Open
Abstract
AIMS In previous studies, the histamine-3 receptor antagonist CEP-26401 had a subtle effect on spatial working memory, with the best effect seen at the lowest dose tested (20 μg), and a dose-dependent disruption of sleep. In the current study, 3 low-dose levels of CEP-26401 were compared with modafinil and donepezil. METHODS In this double-blind, placebo- and positive-controlled, randomized, partial 6-way cross-over study, 40 healthy subjects received single doses of placebo, CEP-26401 (5, 25 or 125 μg) or modafinil 200 mg or donepezil 10 mg. Pharmacokinetic and pharmacodynamic measurements were performed predose and at designated time points postdose. RESULTS The main endpoint between-errors of the spatial working memory-10-boxes task only improved for the 125 μg dose of CEP-26401 with a difference of 2.92 (confidence interval [CI] -1.21 to 7.05), 3.24 (CI -1.57 to 8.04) and 7.45 (CI 2.72 to 12.19) for respectively the 5, 25 and 125 μg dose of CEP-26401, -1.65 (CI -0.572 to 1.96) for modafinil and - 3.55 (CI -7.13 to 0.03) for donepezil. CEP-26401 induced an improvement of adaptive tracking, saccadic peak velocity and reaction time during N-back, but a dose-related inhibition of sleep and slight worsening of several cognitive parameters at the highest dose. CEP-26401 significantly changed several subjective visual analogue scales, which was strongest at 25 μg, causing the same energizing and happy feeling as modafinil, but with a more relaxed undertone. DISCUSSION Of the doses tested, the 25 μg dose of CEP-26401 had the most optimal balance between favourable subjective effects and sleep inhibition. Whether CEP-26401 can have beneficial effects in clinical practice remains to be studied.
Collapse
Affiliation(s)
| | - Rob Zuiker
- Centre for Human Drug Research, Leiden, Netherlands
| | | | - Nicholas Gross
- Research and Development Teva Pharmaceuticals, Frazer, Philadelphia, USA
| | - Ronghua Yang
- Research and Development Teva Pharmaceuticals, Frazer, Philadelphia, USA
| | - Michael Fetell
- Research and Development Teva Pharmaceuticals, Frazer, Philadelphia, USA
| | - Ari Gershon
- Global Patient Safety and Pharmacovigilance, Teva Pharmaceuticals, Petah Tikva, Israel.,Formerly Global Patient Safety and Pharmacovigilance, Teva Pharmaceuticals, Petah Tikva, Israel
| | | | - Edward Hellriegel
- Research and Development Teva Pharmaceuticals, West Chester, Pennsylvania, USA
| | | |
Collapse
|
4
|
Roy S, Paul B, Mukherjee A, Kundu B, Talukdar A. Copper-catalyzed selective C–N bond formation with 2-amino, 2-hydroxy and 2-bromo-5-halopyridine. RSC Adv 2017. [DOI: 10.1039/c7ra08482j] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Copper catalyzed 1,2-diol promoted amination at electron-rich C-5 position of unprotected 2-amino/2-hydroxy-5-halopyridine and selective amination at C-5 in 2-bromo-5-iodopyridine provided excellent yields.
Collapse
Affiliation(s)
- Swarnali Roy
- Department of Organic and Medicinal Chemistry
- CSIR-Indian Institute of Chemical Biology
- Kolkata 700032
- India
| | - Barnali Paul
- Department of Organic and Medicinal Chemistry
- CSIR-Indian Institute of Chemical Biology
- Kolkata 700032
- India
- Academy of Scientific and Innovative Research
| | - Ayan Mukherjee
- Department of Organic and Medicinal Chemistry
- CSIR-Indian Institute of Chemical Biology
- Kolkata 700032
- India
- Academy of Scientific and Innovative Research
| | - Biswajit Kundu
- Department of Organic and Medicinal Chemistry
- CSIR-Indian Institute of Chemical Biology
- Kolkata 700032
- India
| | - Arindam Talukdar
- Department of Organic and Medicinal Chemistry
- CSIR-Indian Institute of Chemical Biology
- Kolkata 700032
- India
- Academy of Scientific and Innovative Research
| |
Collapse
|
5
|
|
6
|
Hudkins RL, Josef KA, Becknell NC, Aimone LD, Lyons JA, Mathiasen JR, Gruner JA, Raddatz R. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity. Bioorg Med Chem Lett 2014; 24:1303-6. [PMID: 24513042 DOI: 10.1016/j.bmcl.2014.01.061] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Revised: 01/16/2014] [Accepted: 01/21/2014] [Indexed: 02/01/2023]
Abstract
A series of fused cyclopropyl-4,5-dihydropyridazin-3-one (3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one) phenoxypiperidine analogs was designed and synthesized, leading to the identification of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a) as a second-generation pyridazin-3-one H3R antagonist. Compound R,S-4a was a potent H3R functional antagonist in vivo in the rat dipsogenia model, demonstrated potent wake activity in the rat EEG/EMG model, and enhanced short-term memory in the rat social recognition memory model at doses as low as 0.03-0.3 mg/kg po.
Collapse
Affiliation(s)
- Robert L Hudkins
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | - Kurt A Josef
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Nadine C Becknell
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Lisa D Aimone
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Jacquelyn A Lyons
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Joanne R Mathiasen
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - John A Gruner
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| | - Rita Raddatz
- Discovery and Product Development, Teva Pharmaceutical Global R&D, 145 Brandywine Parkway, West Chester, PA 19380, USA
| |
Collapse
|
7
|
Arsenyan P, Vasiljeva J, Shestakova I, Domracheva I, Belyakov S. The Synthesis and Cytotoxic Properties of Selenopheno[3,2-c]- and Selenopheno-[2,3-c]quinolones*. Chem Heterocycl Compd (N Y) 2014. [DOI: 10.1007/s10593-014-1419-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
8
|
Josef KA, Aimone LD, Lyons J, Raddatz R, Hudkins RL. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists. Bioorg Med Chem Lett 2012; 22:4198-202. [DOI: 10.1016/j.bmcl.2012.04.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 03/23/2012] [Accepted: 04/02/2012] [Indexed: 10/28/2022]
|
9
|
Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists. Bioorg Med Chem 2012; 20:3880-6. [DOI: 10.1016/j.bmc.2012.04.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 04/04/2012] [Accepted: 04/10/2012] [Indexed: 12/12/2022]
|
10
|
Dandu RR, Lyons JA, Raddatz R, Huang Z, Aimone LD, Hudkins RL. Synthesis and evaluation of a new series of 1′-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4′-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists. Bioorg Med Chem Lett 2012; 22:2151-3. [DOI: 10.1016/j.bmcl.2012.01.139] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Revised: 01/30/2012] [Accepted: 01/31/2012] [Indexed: 11/24/2022]
|
11
|
Hudkins RL, Zulli AL, Dandu RR, Tao M, Josef KA, Aimone LD, Haltiwanger RC, Huang Z, Lyons JA, Mathiasen JR, Raddatz R, Gruner JA. 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity. Bioorg Med Chem Lett 2012; 22:1504-9. [PMID: 22290075 DOI: 10.1016/j.bmcl.2012.01.026] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Revised: 01/04/2012] [Accepted: 01/09/2012] [Indexed: 11/25/2022]
Abstract
Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H(3)R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H(3)R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip.
Collapse
Affiliation(s)
- Robert L Hudkins
- Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Becknell NC, Dandu RR, Lyons JA, Aimone LD, Raddatz R, Hudkins RL. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists. Bioorg Med Chem Lett 2011; 22:186-9. [PMID: 22153342 DOI: 10.1016/j.bmcl.2011.11.038] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Revised: 11/08/2011] [Accepted: 11/09/2011] [Indexed: 12/31/2022]
Abstract
A novel class of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues were designed and synthesized as H(3)R antagonists. Structure-activity relationship identified sulfone 27 with excellent H(3)R affinities in both humans and rats, and acceptable pharmacokinetic properties. Further, compound 28 achieved single digit nanomolar H(3)R affinities in both species with minimum hERG activity.
Collapse
Affiliation(s)
- Nadine C Becknell
- Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | | | | | | | | | | |
Collapse
|